DBV Technologies Receives IND Clearance from FDA to Begin Clinical Trial in Peanut Allergy
7/6/2010 11:14:24 AM
PARIS--(BUSINESS WIRE)--DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
comments powered by